Hill Stanley E, Kirsten La
Long Beach Memorial Medical Center, Department of Inpatient Pharmacy, 2801 Atlantic Ave. Long Beach, CA 90806, USA.
Curr Drug Saf. 2014;9(3):236-9. doi: 10.2174/1574886309666140601210750.
Migraine is a potentially debilitating neurologic disorder affecting approximately 12% of the United States population. Sumatriptan manufacturer-provided drug information states that life threatening arrhythmias, including ventricular tachycardia and ventricular fibrillation (VF), have been reported. A literature search revealed only seven reported cases of ventricular arrhythmias immediately after sumatriptan administration. Twenty minutes after a 42 year old female received sumatriptan, her femoral pulses were not palpable and the electrocardiograph (EKG) showed torsades de pointes followed by VF. After defibrillation and one round of cardiopulmonary resuscitation (CPR), the patient regained spontaneous circulation. The patient was eventually discharged home. Despite studies concluding that sumatriptan has minimal effects on coronary arteries, several cases of sumatriptan-associated myocardial infarction have been documented. In addition, a small number of documented cases have reported life threatening arrhythmias and cardiorespiratory arrest after sumatriptan administration.
偏头痛是一种可能使人衰弱的神经系统疾病，影响着约12%的美国人口。舒马曲坦制造商提供的药物信息表明，已报告有危及生命的心律失常，包括室性心动过速和心室颤动（VF）。文献检索仅发现7例在使用舒马曲坦后立即出现室性心律失常的报告病例。一名42岁女性在使用舒马曲坦20分钟后，股动脉搏动无法触及，心电图（EKG）显示尖端扭转型室速，随后发展为心室颤动。经过除颤和一轮心肺复苏（CPR）后，患者恢复了自主循环。该患者最终出院回家。尽管研究得出结论称舒马曲坦对冠状动脉影响极小，但已有多例舒马曲坦相关心肌梗死的记录。此外，少数记录在案的病例报告了使用舒马曲坦后出现危及生命的心律失常和心肺骤停。
